Autopsy report · NCT03245385

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.

“Sponsors decision”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 6 months before it stopped.
20 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Sun Pharmaceutical Industries Limited
Sponsor type: Industry
Conditions: Atopic Dermatitis
Interventions: Treatment with Halobetasol propionate 0.05% topical spray
Participants: 20
Sites: 13
Countries: United States

Trials that died the same way

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
“Sponsor Decision” (93% match in meaning)

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.